Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.66 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17109789 | 0.98 | CASP2 (0.69) | CASP2NAAACNR1MEN1KMT2A | |
| SCHEMBL4904632 | 0.94 | CASP2 (0.62) | CASP2NAAACNR1MEN1KMT2A | |
| SCHEMBL21155006 | 0.93 | CASP2 (0.56) | CASP2NAAACNR1ALDH1A1FAAH | |
| SCHEMBL19249120 | 0.91 | CASP2 (0.58) | CASP2NAAACNR1MEN1KMT2A | |
| SCHEMBL20392005 | 0.91 | CASP2 (0.69) | CASP2NAAACNR1MEN1KMT2A | |
| SCHEMBL18313728 | 0.90 | ALDH1A1 (0.52) | CASP2NAAACNR1MEN1KMT2A | |
| SCHEMBL18313754 | 0.89 | CASP2 (0.67) | CASP2NAAACNR1FAAHEPHX1 | |
| SCHEMBL28393843 | 0.89 | CASP2 (0.61) | CASP2NAAACNR1MEN1KMT2A | |
| SCHEMBL28340110 | 0.89 | CASP2 (0.61) | CASP2NAAACNR1FAAHEPHX1 | |
| SCHEMBL19239689 | 0.88 | ALDH1A1 (0.55) | CASP2NAAACNR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4122925-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | Medshine Discovery Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-9593156-B2 | Insulin analog dimers | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150274802-A1 | INSULIN ANALOG DIMERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | CASP2 1881/4885NAAA 3661/4885CNR1 4065/4885 |
| US-20150274802-A1 | INSULIN ANALOG DIMERS | INSR, IAPP, GPR119 | CASP2 4093/4885NAAA 1811/4885CNR1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.